Ignite Planners LLC Sells 19 Shares of Eli Lilly and Company (NYSE:LLY)

Ignite Planners LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 1.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,948 shares of the company’s stock after selling 19 shares during the period. Ignite Planners LLC’s holdings in Eli Lilly and Company were worth $1,725,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Capital Planning LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $262,000. CHURCHILL MANAGEMENT Corp bought a new stake in Eli Lilly and Company in the 1st quarter valued at $6,916,000. M&G Plc bought a new stake in Eli Lilly and Company in the 1st quarter valued at $8,896,000. HighPoint Advisor Group LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $9,878,000. Finally, Leo Wealth LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter worth about $3,355,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $898.40 on Tuesday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The firm has a 50 day simple moving average of $900.13 and a 200 day simple moving average of $848.40. Eli Lilly and Company has a fifty-two week low of $547.61 and a fifty-two week high of $972.53. The firm has a market cap of $853.84 billion, a P/E ratio of 132.31, a P/E/G ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Sell-side analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on LLY shares. Bank of America increased their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Wells Fargo & Company increased their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Citigroup started coverage on Eli Lilly and Company in a research note on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price target on the stock. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, Morgan Stanley reissued an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.